Phase I trials showed that dapoxetine had neither clinical significant electrocardiographic effects nor delayed repolarization effects, with dosing up to four-fold greater than the maximum recommended dosage which is 60 mg.
Fase I forsøg viste, at dapoxetin hverken havde elektrokardiografisk eller forsinket repolariseringsspors virkning af klinisk betydning, selv med dosering fire gange højere end den maksimale anbefalede dosis på 60 mg.